A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis
Administered By
Awarded By
Contributors
- Salama, April Kelly Scott Principal Investigator
Start/End
- October 31, 2019 - June 29, 2021